摘要
脊索瘤是一种罕见的骨肿瘤,起源于胚胎脊索残留组织。这类肿瘤通常生长在靠近重要血管和神经的解剖复杂区域,使得手术完全切除极具挑战性。此外,脊索瘤对放射治疗和化学药物治疗反应不佳,导致其高复发率和较差预后。目前治疗手段有限,亟需新型研究模型以深入理解其发病机制并开发更有效疗法。传统细胞系模型无法准确模拟脊索瘤的体内特征,而类器官技术为疾病建模和药物筛选提供了新途径。该文详述了从患者肿瘤组织建立脊索瘤类器官的方案,包括组织消化、类器官培养、传代及特定基因表达验证等流程。通过该方法成功构建了脊索瘤类器官模型,同时经检测证实了其表达Brachyury和KRT19等脊索瘤特异性标志物,表明了该模型能真实再现体内肿瘤特征。该模型为研究脊索瘤发生发展的分子机制及药物研发提供了重要的体外研究平台。
Chordoma is a rare type of bone tumor that arises from remnants of the embryonic notochord.These tumors typically develop in anatomically challenging locations near the critical blood vessels and nerves,making complete surgical removal difficult.Additionally,chordomas are generally unresponsive to radiotherapy and chemotherapy,leading to high rates of recurrence and poor overall prognosis.Current treatment options for chor-doma are limited,underscoring the urgent need for novel research models to better understand its pathogenesis and to develop more effective therapies.Traditional cell line models fail to accurately mimic the in vivo characteristics of chordoma,whereas organoid technology offers promising new avenues for disease modeling and drug screening.Here,describe a protocol for generating chordoma organoids from patient tumor tissues,detailing processes such as tissue dissociation,organoid culture and passage,and verification of specific gene expression.Using this method,Chordoma organoid models were successfully established and confirmed to express chordoma-specific markers such as Brachyury and KRT19,demonstrating their ability to faithfully recapitulate the features of in vivo tumors.This model provides an important in vitro research platform for studying the molecular mechanisms of chordoma development and progression,as well as for drug development.
作者
毛永鑫
李俊晓
许炜
MAO Yongxin;LI Junxiao;XU Wei(School of Clinical Medicine,Shandong Second Medical University,Weifang 261000,China;Department of Orthopedic Oncology,the Second Affiliated Hospital of Naval Medical University,Shanghai 200003,China)
出处
《中国细胞生物学学报》
2025年第12期3213-3221,共9页
Chinese Journal of Cell Biology
基金
上海市2022年度“曙光计划”(批准号:22SG36)资助的课题。
